In any case, our approaches and findings reveal potential cancer therapeutic strategies, single agent or combination, for some SF3b-targeting splicing modulators based on a molecular mechanism underlying differential sensitivity of BCL2 family genes to splicing modulation. Here, BCL2 is linked to cancer.